Aperio Group LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 905,862 shares of the biopharmaceutical company’s stock after buying an additional 119,265 shares during the period. Aperio Group LLC owned 0.07% of Gilead Sciences worth $73,393,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of GILD. BlackRock Inc. boosted its position in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after buying an additional 310,607 shares in the last quarter. FMR LLC lifted its holdings in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. 75.94% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 494,999 shares of company stock worth $37,404,139 over the last three months. 1.30% of the stock is currently owned by insiders.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.71 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market cap of $95,383.76, a price-to-earnings ratio of 8.28, a P/E/G ratio of -1.22 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period last year, the firm posted $2.75 EPS. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.69%.

GILD has been the topic of a number of research reports. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a report on Monday, August 28th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Credit Suisse Group set a $79.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, August 28th. Robert W. Baird reiterated an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $85.03.

TRADEMARK VIOLATION NOTICE: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/24/aperio-group-llc-has-73-39-million-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.